Innovent Biologics Inc (6IB) - Total Liabilities

Latest as of December 2025: €17.99 Billion EUR ≈ $21.03 Billion USD

Based on the latest financial reports, Innovent Biologics Inc (6IB) has total liabilities worth €17.99 Billion EUR (≈ $21.03 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Innovent Biologics Inc (6IB) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Innovent Biologics Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how Innovent Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Innovent Biologics Inc asset portfolio.

Innovent Biologics Inc Competitors by Total Liabilities

The table below lists competitors of Innovent Biologics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Woori Financial Group Inc KO:316140	Korea	₩549.80 Trillion
International Paper NYSE:IP	USA	$22.07 Billion
KGHM Polska Miedz SA WAR:KGH	Poland	zł25.34 Billion
OMV AG ADR 1 F:OMVI	Germany	€21.37 Billion
SBI Life Insurance Company Limited NSE:SBILIFE	India	Rs5.14 Trillion
WSP Global Inc TO:WSP	Canada	CA$10.56 Billion
Tower Semiconductor Ltd TA:TSEM	Israel	ILA700.06 Million
Tourmaline Oil Corp. TO:TOU	Canada	CA$7.10 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Innovent Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 6IB equity to assets ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.62	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.93	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.48	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Innovent Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Innovent Biologics Inc (2016–2025)

The table below shows the annual total liabilities of Innovent Biologics Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€17.99 Billion ≈ $21.03 Billion	+112.04%
2024-12-31	€8.48 Billion ≈ $9.92 Billion	+4.75%
2023-12-31	€8.10 Billion ≈ $9.47 Billion	+18.09%
2022-12-31	€6.86 Billion ≈ $8.02 Billion	+15.99%
2021-12-31	€5.91 Billion ≈ $6.91 Billion	+93.55%
2020-12-31	€3.06 Billion ≈ $3.57 Billion	+23.47%
2019-12-31	€2.47 Billion ≈ $2.89 Billion	+29.00%
2018-12-31	€1.92 Billion ≈ $2.24 Billion	-52.98%
2017-12-31	€4.08 Billion ≈ $4.77 Billion	+8.09%
2016-12-31	€3.77 Billion ≈ $4.41 Billion	--

About Innovent Biologics Inc

F:6IB Germany Biotechnology

Market Cap

$21.18 Billion

€18.11 Billion EUR

Market Cap Rank

#1416 Global

#318 in Germany

Share Price

€10.40

Change (1 day)

+2.83%

52-Week Range

€7.96 - €11.96

All Time High

€11.96